OGEN ORAGENICS INC.

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.

These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.

2025 BIO International Convention

  • Dates: June 16–19, 2025

  • Location: Boston Convention & Exhibition Center, Boston, MA

  • Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET

  • Registration:

42nd Annual National Neurotrauma Society (NNS) Symposium

  • Dates: June 15–18, 2025

  • Location: Philadelphia Marriott Downtown, Philadelphia, PA

  • Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit .

Investor Contact:

Rich Cockrell

CG Capital

866.889.1972

tal



EN
10/06/2025

Underlying

OGENORAGENICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ORAGENICS INC.

 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics to Present at 2025 BIO International Convention and Attend 4...

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15...

June 10, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the “Board”) on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the Company’s common stock is expecte...

May 28, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Dru...

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a ...

May 13, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to D...

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A SARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on Tuesday, May 20, 2025 at 4:00 PM ET to discuss the growing unmet ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Inju...

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual Traumatic Brain Injury Conference, taking place May 5-6, 2025 in Boston, MA. Hosted by Arrowhead Sci-Tech Conferences & Events, the Annual Traumatic Brain Injury Conference brings together global leaders from academia, industry, government, and the military to ...

April 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch